On March 15, 2026, the Pharmaceutical Committee of the China-Europe Business Association was officially established in Shanghai. The establishment

 of this committee marks a further deepening of the Association’s specialized service capabilities in the healthcare and pharmaceutical sector, and 

provides an important platform for advancing collaboration and coordinated development between the Chinese and European pharmaceutical 

industries.

Amid the ongoing transformation of the global pharmaceutical landscape and the increasing emphasis on innovation-driven growth, Chinese 

pharmaceutical companies are accelerating their global expansion and actively integrating into international value chains. Meanwhile, Europe 

maintains strong advantages in innovative drug development, clinical systems, and regulatory frameworks. The complementary strengths between 

China and Europe continue to expand, creating significant opportunities for collaboration.

Against this backdrop, the newly established Pharmaceutical Committee will focus on key areas of China-Europe pharmaceutical cooperation, including

 innovative drug R&D, medical devices, active pharmaceutical ingredients (APIs) and formulations, cross-border regulatory approval and compliance, 

as well as industrial investment and M&A. The Committee aims to build a systematic service and exchange mechanism by integrating resources across 

the entire industry value chain, connecting enterprises, research institutions, investors, and government stakeholders.

According to the Association, the Pharmaceutical Committee will prioritize several core initiatives: promoting joint R&D and technology collaboration 

between Chinese and European companies to accelerate innovation commercialization; establishing a cross-border regulatory and compliance support

 system to facilitate market entry in both directions; organizing industry matchmaking events and thematic forums to deepen exchanges; and 

mobilizing global resources to support investment cooperation and industrial project implementation.

A representative of the China-Europe Business Association noted that the pharmaceutical industry is characterized by high technical barriers and 

stringent regulatory requirements, posing significant challenges for companies pursuing international expansion. Leveraging its extensive network 

across China and Europe, the Pharmaceutical Committee will provide more specialized, precise, and comprehensive support to help companies 

mitigate risks and enhance their global operational efficiency.

Industry observers believe that the establishment of the Committee will further promote deep integration of China-Europe pharmaceutical value 

chains, playing a positive role in advancing technological innovation, raising industry standards, and optimizing global resource allocation. It is also 

expected to provide strong support for Chinese pharmaceutical companies to enhance their global competitiveness and achieve high-quality 

international expansion.

Looking ahead, the Pharmaceutical Committee will continue to refine its service framework and promote the implementation of practical cooperation 

projects, contributing to the development of an open, collaborative, and mutually beneficial China-Europe pharmaceutical ecosystem.